ImmunityBio shares are trading higher after the company announced it dosed its first patients in its Phase 1 clinical study of CAR-NK cell therapy for relapsed B-Cell Non-Hodgkin Lymphoma.
Portfolio Pulse from Benzinga Newsdesk
ImmunityBio shares rose as the company dosed its first patients in a Phase 1 clinical study of CAR-NK cell therapy for relapsed B-Cell Non-Hodgkin Lymphoma.
October 24, 2024 | 2:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ImmunityBio's stock is trading higher following the initiation of its Phase 1 clinical study for a new CAR-NK cell therapy targeting relapsed B-Cell Non-Hodgkin Lymphoma.
The initiation of a clinical study is a significant milestone for biotech companies, often leading to positive investor sentiment and stock price increases. The news directly pertains to ImmunityBio's progress in developing a new therapy, which is crucial for its growth and valuation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100